What РЕЗОЛОР Treats: Main Uses and Benefits

The primary therapeutic domain for РЕЗОЛОР is the symptomatic management of chronic (long-term) constipation in adults for whom standard laxatives have generally failed to provide adequate relief. The medication is applied in scenarios where additional management of discomfort is required due to symptoms related to severe constipation.

---

This medicine is considered relevant in clinical settings marked by the severe and persistent nature of Chronic Idiopathic Constipation (CIC). It is used for managing symptoms that create noticeable physiological strain, specifically infrequent bowel movements, significant straining, and the persistent sensation of incomplete evacuation. The therapeutic benefit is relevant for easing symptoms that create noticeable physiological strain, and it contributes to improved comfort during symptomatic periods by assisting with more spontaneous evacuations and easing the sensation of incomplete emptying. This supportive relief contributes to easing the overall symptom load during symptomatic phases.

---

Fact Focus: Use Context for Chronic Constipation The medicine is applied in scenarios requiring sustained management when symptoms of chronic constipation are refractory to conventional treatments.

Who Can and Cannot Use РЕЗОЛОР?

Official regulatory documents define strict population eligibility criteria for РЕЗОЛОР (Prucalopride). The medicine is approved only for use in adults aged 18 years and older. Use is generally not recommended for children and adolescents under 18.

Absolute Contraindications

The medicine must not be used if you have a known hypersensitivity to Prucalopride or any of its components.

Use is absolutely contraindicated in patients with severe, existing gastrointestinal conditions, including:

• Intestinal perforation or obstruction.
• Obstructive ileus.
• Severe inflammatory conditions of the intestinal tract, such as Crohn's disease, ulcerative colitis, or toxic megacolon/megarectum.

Use is also prohibited for patients with renal impairment requiring dialysis (end-stage renal disease).

Conditional or Restricted Use

Certain populations require conditional use, often involving dose adjustment or increased caution:

• Patients with severe renal impairment (not requiring dialysis) or severe hepatic impairment require conditional use.
• The medicine is not recommended during pregnancy or breastfeeding. Women of childbearing potential are required to use effective contraception during treatment.
• Caution is advised when prescribing to patients with a history of arrhythmias or ischaemic cardiovascular disease, or those with severe and clinically unstable concomitant diseases.

Interactions with other medicines and products for РЕЗОЛОР (Prucalopride)

This section summarizes the officially documented interactions for РЕЗОЛОР (prucalopride) based on regulatory information.

Pharmacokinetic Interaction Profile

РЕЗОЛОР has a low potential for causing or being affected by clinically significant drug interactions. It is not an inhibitor of CYP450 enzymes at therapeutic concentrations and is mainly eliminated unchanged through the kidneys.

Category	Regulatory Finding
P-gp/BCRP Substrate	A weak substrate of P-glycoprotein (P-gp) and BCRP
CYP450 Effect	No inhibitory effect on key CYP450 enzymes

Specific Interacting Substances

Co-administration with potent P-gp inhibitors, such as ketoconazole, results in an increase of РЕЗОЛОР's systemic exposure (AUC) by approximately 40%. This is attributed to the inhibition of P-gp mediated renal transport. The magnitude of this exposure increase is generally considered too small to be clinically relevant for most patients, but the potential effect of other potent P-gp inhibitors must be considered.

Concomitant use with Erythromycin has also been noted to increase РЕЗОЛОР plasma concentrations by 30-40%.

Pharmacodynamic (PD) and Other Constraints

• QTc Prolongation: Caution should be exercised when co-administering РЕЗОЛОР with medicines that are known to prolong the QTc interval, due to a potential risk of additive PD effects.
• Oral Contraceptives: In cases of severe diarrhea induced by treatment, the effectiveness of oral contraceptives may be reduced, requiring the use of an additional method of contraception.

Selective Receptor Activation and Gastrointestinal Motility

The mechanism involves the drug acting as a selective agonist for serotonin 5-HT4 receptors predominantly found on enteric nerve cells within the wall of the gastrointestinal tract. By selectively binding to and activating these receptors, the drug initiates a signal within the Enteric Nervous System (ENS).

Activation of the 5-HT4 receptors promotes the release of the pro-motility neurotransmitter acetylcholine from the enteric neurons. This increased availability of acetylcholine enhances the strength and frequency of contractions in the smooth muscle layers of the colon, thereby increasing the rate of content transit.

This targeted stimulation of muscle action results in an increase in the speed of contents moving through the large intestine, known as colonic transit. This action specifically triggers high-amplitude wave-like muscle movements (Giant Migrating Contractions) that are the primary physiological mechanism for content propulsion through the colon, shaping the resulting physiological effect.

Administration Guidelines for РЕЗОЛОР (Prucalopride)

РЕЗОЛОР is an oral medication taken as film-coated tablets. It is approved for use only in adults (18 years and older).

Official Dosing and Administration

Patient Population	Recommended Oral Dose	Administration Notes
Standard Adults	2 mg once daily	May be taken with or without food and at any time of the day.
Elderly (over 65 years)	Start with 1 mg once daily; may increase to 2 mg once daily if needed.
Severe Renal Impairment (CrCL < 30 mL/min)	1 mg once daily
Severe Hepatic Impairment (Child-Pugh Class C)	Start with 1 mg once daily; may increase to 2 mg once daily if needed.

Procedural and Treatment Rules

1. Take the film-coated tablet whole with water by mouth. The dose should not exceed 2 mg daily, as higher doses are not expected to increase efficacy.
2. Missed Dose: If a dose is missed, take the next scheduled dose at the usual time. Do not take a double dose to make up for the forgotten one.
3. Treatment Reassessment: If the 2 mg once-daily dose is not effective after 4 weeks, the patient should be re-examined and the benefit of continuing treatment must be reconsidered by a healthcare provider. The benefit of prolonged treatment (beyond 3 months) should be reassessed at regular intervals.
4. Contraception: Women of childbearing potential should use a reliable method of contraception during treatment.

Research Evidence / Overview of Studies for РЕЗОЛОР (Prucalopride)

Evidence for Use in Chronic Idiopathic Constipation (CIC) in Adults

The core research in studies evaluating the use of РЕЗОЛОР has focused on adults experiencing Chronic Idiopathic Constipation (CIC), particularly those who have not found adequate relief from standard laxative treatments. The evidence base is primarily built upon a series of short-term, placebo-controlled Randomized Controlled Trials (RCTs). These trial designs are used for providing initial measurements in the presence of the active substance compared to placebo, which involve a comparison between the active substance and an inactive control (placebo).

In these research settings, РЕЗОЛОР was evaluated in studies examining patient-reported experiences related to CIC. Findings describe patterns observed in the studies related to changes in bowel function compared to patients who received placebo. However, the research provides insight into short-term changes only. These pivotal studies typically had follow-up durations that were limited to a few months (e.g., 12 weeks).

---

Primary Outcomes Measured in Clinical Trials

The research monitored symptoms over time by focusing on several specific, measurable criteria. Researchers primarily measured the proportion of patients who achieved a critical functional goal: an average of three or more Spontaneous Complete Bowel Movements (SCBMs) per week. This specific outcome was the primary metric used in research exploring short-term symptom changes.

Secondary outcomes monitored physiological strain or stress. Research also examined changes in patient-reported symptoms, such as straining, bloating, and abdominal discomfort. Patient-reported outcomes describing perceived discomfort were measured using standardized questionnaires like the Patient Assessment of Constipation Quality of Life (PAC-QOL) instrument. Studies report how symptoms evolved in the observed populations across these various measures, and studies contribute to the broader evidence landscape.

---

What is Still Uncertain About РЕЗОЛОР Research

A key gap in the research is the lack of extensive, long-term, placebo-controlled research data. While observational and open-label studies exist for extended use, the certainty remains low when compared against controlled trials. Additionally, data for certain groups remain insufficient. For instance, evidence is limited for specific demographic groups such as older adults with multiple chronic health issues. Dedicated research has also examined the use of Prucalopride in children and adolescents (the pediatric population), and data are still emerging in this area.

Key Studies & References Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials

Common questions about РЕЗОЛОР (FAQ)

Q: What kind of constipation is РЕЗОЛОР specifically intended to treat?

Official product information states that РЕЗОЛОР is indicated for the symptomatic treatment of a condition known as chronic idiopathic constipation (CIC). This treatment is intended for use in adults when standard laxative treatments have failed to provide adequate relief from symptoms.

---

Q: Is РЕЗОЛОР considered a type of laxative, and if not, how is it different?

РЕЗОЛОР is classified as a prokinetic agent, which is a type of motor stimulant for the bowel. It works by selectively activating specific serotonin receptors in the gut wall, setting it apart from traditional bulk-forming or osmotic laxatives. It is typically considered when other common laxatives have proven ineffective.

---

Q: Does the effect of РЕЗОЛОР wear off over time (long-term use)?

Official data on long-term controlled studies are limited, but the drug's effect is not known to immediately wear off while in use. If treatment is discontinued, the effects on bowel function return to pre-treatment levels within about one week. The necessity for continued treatment is subject to regular benefit reassessment by a healthcare provider.

---

Q: Can РЕЗОЛОР be taken indefinitely for chronic constipation?

The need for continued use is subject to regular benefit reassessment by a healthcare provider. Official guidelines state that if a patient does not respond effectively after the initial period (e.g., four weeks), the continuation of treatment must be re-evaluated by a clinician.

---

Q: What should be done if a rash or allergic reaction occurs after taking РЕЗОЛОР?

Cases of hypersensitivity and allergic reactions have been reported, including symptoms like rash, itching, hives, or swelling of the face or lips. Official safety information regarding severe allergic reactions emphasizes the need for immediate professional medical attention.

---

Q: Is there a link between РЕЗОЛОР and a change in heart rhythm?

Official safety documents list palpitations (a feeling of a fast or irregular heartbeat) as an uncommon side effect. Regulatory documents mention caution for use in individuals with a history of heart rhythm issues (arrhythmias) or ischaemic cardiovascular disease.

---

Q: What percentage of patients in clinical trials reported a significant benefit from РЕЗОЛОР?

Clinical studies measured benefit using a primary goal: achieving three or more spontaneous complete bowel movements per week over a period of 12 weeks. In these pivotal studies, approximately 24% of adult patients achieved this specific functional goal compared to placebo.

---

Q: Does РЕЗОЛОР cause weight gain or weight loss as a side effect?

Official safety documents report decreased appetite (Anorexia) as an uncommon side effect. Significant changes in body weight are not listed among the commonly reported adverse reactions in the official product information.

---

Q: Does РЕЗОЛОР affect the absorption of other oral medications?

The active ingredient is not known to inhibit the major enzyme systems (CYP450) responsible for metabolizing other drugs, giving it a low potential to affect their absorption. While it is a weak substrate of certain transport proteins, this interaction is generally not considered to be clinically significant.

---

Q: What are the common symptoms of 'toxic megacolon' or 'megarectum' that make РЕЗОЛОР unsafe?

РЕЗОЛОР is strictly contraindicated if conditions like toxic megacolon or megarectum are already present. These conditions represent severe underlying intestinal pathology, and symptoms can include fever, a very fast heart rate, and extreme abdominal pain or distension.

---

Q: Why is there a warning about suicidal thoughts and tendencies on the medication leaflet for РЕЗОЛОР?

Although a definitive causal link has not been established, regulatory documents state that reports of suicides, suicide attempts, and suicidal ideation have occurred. Official safety documents include a warning that monitoring may be necessary for the persistent worsening of depression or the emergence of suicidal behaviors.

---

Q: Are there any reported psychological or mood-related side effects with РЕЗОЛОР?

Post-marketing safety reports list several psychiatric disorders. These can include anxiety, depression, insomnia, nightmares, and suicidal ideation.

---

Q: Can РЕЗОЛОР be used if a person has a history of depression or other mood disorders?

Regulatory documents mention caution when the drug is considered for individuals with a history of severe depression, suicidal thoughts, or suicidal behavior. The need for monitoring for any worsening of depression is noted in the official information.

---

Q: What is the half-life of РЕЗОЛОР in the body?

According to official pharmacokinetic studies, the half-life of the active ingredient, Prucalopride, is approximately 18 to 20 hours. This refers to the time it takes for half of the dose to be eliminated from the body.

---

Q: What symptoms might be experienced in the event of taking too much РЕЗОЛОР?

Taking a dose higher than prescribed may result in an intensification of the known side effects. Official information indicates that symptoms of overdose primarily include headache, nausea, diarrhea, and vomiting.

---

Q: Can РЕЗОЛОР affect a person's ability to drive or operate machinery?

Official documents note that because common side effects include dizziness and fatigue (tiredness), caution regarding the ability to drive or operate complex machinery is mentioned in the product information.

Storage and Disposal Conditions for REZOLOR (Prucalopride)

REZOLOR must be stored according to specific regulatory requirements to maintain product quality and safety, and handling must follow defined pharmaceutical waste rules.

---

Storage Requirements

• Temperature and Protection: The medicine must not be stored at a temperature that exceeds 30 C. The tablets must be kept in the original blister package to protect them from moisture.
• Child Safety: It is mandatory to keep REZOLOR out of the sight and reach of children.
• Stability: The labeled shelf life for the film-coated tablets is 4 years, and the product must not be used after the expiry date printed on the packaging.

---

Disposal Instructions

Official instructions for disposal state that unused or expired medicine must not be thrown away via wastewater or household waste. These measures help protect the environment. To ensure correct pharmaceutical waste disposal, patients are required to ask a pharmacist how to properly discard the unused product.